Skip to main content
Nectar Lifesciences Limited logo

Nectar Lifesciences Limited — Investor Relations & Filings

Ticker · NECLIFE ISIN · INE023H01027 LEI · 335800RY4LGC64KN9C05 BSE.NS Manufacturing
Open in API
Filings indexed 538 across all filing types
Latest filing 2025-11-27 Transaction in Own Shar…
Country IN India
Listing BSE.NS NECLIFE

About Nectar Lifesciences Limited

https://www.neclife.com/

Nectar Lifesciences Limited is a pharmaceutical organization specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the cephalosporin segment, producing a wide range of oral and sterile products including Cefixime, Cefuroxime Axetil, and Ceftriaxone. Its operations encompass a fully integrated business model supported by large-scale manufacturing facilities that adhere to international regulatory standards such as USFDA and EUGMP. In addition to its core antibiotic portfolio, the company produces menthol and phytochemicals. Nectar Lifesciences serves a global clientele through contract manufacturing and development services, leveraging its research and development capabilities to provide high-quality therapeutic solutions across various international markets.

Recent filings

Filing Released Lang Actions
Board Meeting — Buyback/Other business matters
Transaction in Own Shares Classification · 95% confidence The document is a short announcement from Nectar Lifesciences Ltd. informing the stock exchanges about a proposal for a buyback of equity shares to be considered by the Board of Directors at a future meeting. It references a regulatory requirement (SEBI Listing Obligations and Disclosure Requirements Regulations 2015) and provides no financial data or detailed report content. The document length is only 1562 characters, indicating it is a brief notice rather than a full report. This fits the category of a company announcement regarding capital structure changes, specifically a share buyback proposal. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2025-11-27 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Nectar Lifesciences Ltd. to the National Stock Exchange of India regarding the publication of financial results for the quarter and half year ended September 30, 2025. It includes detailed unaudited consolidated and standalone financial results with figures for income, profit/loss, earnings per share, and other financial metrics. The document mentions that these results have been reviewed and approved by the Board of Directors and subjected to limited review by statutory auditors. The content is substantive financial data for a period shorter than a full fiscal year (quarter and half year), which fits the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement of publication but contains actual financial results and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-11-15 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a formal communication from the company to stock exchanges regarding the outcome of a board meeting held on November 14, 2025. The content specifically details changes in the registered office and corporate office addresses of the company. There is no financial data, no mention of financial results, no audit information, no voting results, no legal proceedings, or any other report type content. The document is an announcement of board decisions, specifically about office location changes, which falls under management or board information disclosures. According to the filing definitions, announcements about changes in the company's board or senior management or related corporate decisions are classified as Board/Management Information (MANG). Although this document does not mention changes in personnel, it is a board meeting outcome announcement about corporate office changes, which is typically classified under MANG rather than Regulatory Filings or other categories. The document length is short (2131 characters), and it is not a report publication announcement or certification. Therefore, the best fit is MANG with high confidence.
2025-11-14 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 91% confidence The document is a board meeting outcome filed under SEBI LODR Regulations 30 and 33, presenting the unaudited standalone and consolidated financial results for the quarter and half‐year ended September 30, 2025, along with auditor review reports and detailed interim financial statements. This is more than a simple earnings highlight or an announcement; it contains substantive interim financial data and analysis, consistent with an Interim/Quarterly Report. H1 2026
2025-11-14 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the completion of a slump sale and asset sale by Nectar Lifesciences Ltd. It references specific agreements (Business Transfer Agreement and Asset Purchase Agreement) and provides final consideration amounts. The document is short (2249 characters) and serves as an announcement of a transaction completion rather than a detailed financial report or analysis. It does not contain financial statements or detailed financial data, nor is it a report or presentation. The content fits the description of a Capital/Financing Update, as it informs about significant changes in the company's assets and business structure due to the sale.
2025-11-13 English
Change in Management
Board/Management Information Classification · 92% confidence The document is a stock exchange disclosure under SEBI LODR Regulation 30 regarding the transfer and resignation of key managerial personnel (KMP) and senior management personnel (SMP) following a business transfer (slump sale). It provides details on changes in the company’s board and senior management, including cessation and new roles. This clearly falls under announcements of changes in board of directors or senior management.
2025-11-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.